Alcon shares fall as tighter eye-care market outlook raises growth concerns

By Reuters News

By Kira Britten and Jesus Calero

- Shares in Swiss eye-care company Alcon ALCC.S fell around 6% on Wednesday as a weaker market outlook clouded its earlier profit upgrades, with analysts pointing to disappointing sales of implantable products such as intraocular lenses used to treat cataracts.

New surgical equipment and eye treatments had helped Alcon raise its earnings forecasts twice this year, but a sluggish US cataract market and continued competition are now testing whether those products can sustain growth.

Alcon CEO David Endicott said in August that US cataract surgery volumes were being held back by retiring surgeons and younger replacements performing fewer operations despite continued demand from patients.

Alcon expects the markets it serves to grow about 3% in 2026, down from between 3% and 4% previously. It also lowered the top end of its annual earnings growth forecast by 1 percentage point to between 12% and 14%.

"All in, we acknowledge Q3 is unlikely to settle the debate around the forward growth path for the company," Citi said in a note to investors.

Third-quarter sales rose 5% to $2.72 billion, but slightly missed market expectations, as sales of implantables fell 2%.

The strength of Alcon's profits also came into question. JPMorgan analysts calculated that its operating profit would have missed expectations by around 9% without a $58 million tariff refund, rather than the slight beat it posted.

The shares were on track for their worst trading day in six months as of 1005 GMT.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.